Epoch Investment Partners Inc. Acquires 5,125 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Epoch Investment Partners Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 185,061 shares of the company’s stock after purchasing an additional 5,125 shares during the period. Epoch Investment Partners Inc. owned approximately 0.22% of IDEXX Laboratories worth $90,162,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Capital Research Global Investors bought a new position in IDEXX Laboratories during the fourth quarter valued at $135,910,000. American Century Companies Inc. increased its position in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after acquiring an additional 177,226 shares during the last quarter. TD Asset Management Inc increased its position in IDEXX Laboratories by 178.8% during the fourth quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock valued at $144,317,000 after acquiring an additional 166,751 shares during the last quarter. Point72 Asset Management L.P. bought a new position in IDEXX Laboratories during the fourth quarter valued at $78,001,000. Finally, 1832 Asset Management L.P. increased its position in IDEXX Laboratories by 4,193.1% during the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock valued at $62,601,000 after acquiring an additional 125,498 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 2.0 %

Shares of IDEXX Laboratories stock opened at $506.74 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm’s 50-day moving average is $483.85 and its two-hundred day moving average is $499.16. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 49.06, a PEG ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the company earned $2.67 earnings per share. The firm’s revenue was up 6.4% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Finally, Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.